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ABSTRACT 
The expression of Human Leukocyte Antigen G (HLA-G) on Fetal Extravillous Trophoblast (EVT) cells 
during pregnancy plays an important role in preventing the fetus from rejection by suppressing the 
maternal immune system. Decreased expression levels of HLA-G have already shown to be associated 
with several complications of pregnancy such as pre-eclampsia. However, it remains largely unknown how 
HLA-G gene expression is regulated with regard to its function and its complications. Polymorphisms and 
microRNAs affect HLA-G gene expression and the formation of isoforms. Interestingly, three microRNAs, 
miR-148a, miR-148b and miR-152, downregulate HLA-G expression with functional consequences. Since 
HLA-G expression levels are reduced in pre-eclampsia without a known cause, we hypothesize that these 
microRNAs are involved in the development of pre-eclampsia. This review discusses how microRNAs can 
affect HLA-G gene expression and its functions. Additionally, the role of microRNAs in the development 
of pre-eclampsia will be reviewed. 
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1. INTRODUCTION 
In pregnancy, the semi-allogenic fetus expresses both 
maternal and paternal antigens. As a consequence, the 
mother induces an immune reaction against the paternal 
antigens of the fetus. To prevent the fetus from rejection, 
tolerance of the maternal immune system is induced by 
fetal trophoblast cells. Fetal Extravillous Trophoblast 
(EVT) cells lack the expression of classical Major 
Histocompatibility Complex (MHC) Ia except for a 
small amount of HLA-C (Ellis et al., 1986; King et al., 
2000). However, EVT cells are able to suppress an 
immunological reaction by the expression of Human 
Leukocyte Antigen G (HLA-G) (Chumbley et al., 
1993; Ellis et al., 1986; Kovats et al., 1990). In 
addition to the ability of repressing the maternal 
immune system, fetal EVT cells are also able to 
invade the maternal decidua in order to remodel the 
uterine arteries (Huppertz et al., 2012). This 
transforms the spiral arteries to large capacity tubes which 
provide the fetus with nutrients, oxygen and it removes 
carbon dioxide and waste products (Huppertz et al., 2012; 
Kumpel and Manoussaka, 2012).  
HLA-G is a non-classical MHC class Ib molecule 
located on chromosome 6. It consists of 8 exons of 
which exons 2, 3 and 4 encode for the α1, α2 and α3 
regions respectively. The α1 and 2 regions bind 
peptides in the peptide binding cleft whereas the α3 
region is responsible for binding the co-receptors 
Immunoglobulin-Like Transcript-2 (ILT2) receptor and 
ILT4 (Clements et al., 2005). Moreover, the α3 region of 
HLA-G has an increased hydrophobicity compared to the 
classical MHCs. This can possibly enhance the affinity of 
the ILT receptors to HLA-G (Clements et al., 2005).  
Seven isoforms of HLA-G can be made via 
alternative splicing (Ishitani and Geraghty, 1992). In 
total there are 4 membrane-bound (HLA-G1-G4) and 3 
soluble (HLA-G5-G7) HLA-G molecules (Fujii et al., 
1994; Ishitani and Geraghty, 1992; Kirszenbaum et al., 
1994; Moreau et al., 1995; Paul et al., 2000). Depending 
on the translation of the mRNA, these isoforms can be 
either membrane-bound or soluble (sHLA-G). Upon 
translation, exon 5, which encodes for the 
transmembrane region, will be incorporated and 
membrane-bound isoforms will be made. However, a 
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stop codon in intron 4 will block further mRNA 
translation and prevents incorporation of exon 5 
thereby creating soluble isoforms (Fujii et al., 1994). 
In addition, soluble HLA-G5 can also be generated by 
proteolytic shedding of HLA-G1 via 
metalloproteinases (Park et al., 2004).  
In contrast to the other isoforms, both HLA-G1 and 
HLA-G5 contain β2-Microglobulin (β2M) which is 
specifically recognized by the ILT2 receptor (Gonen-
Gross et al., 2005). The inhibitory receptors ILT2, ILT4 
and the Killer Immunoglobulin-like Receptor 2DL4 
(KIR2DL4) play an important role in the recognition 
of HLA-G by immune cells (Colonna et al., 1998; 
Navarro et al., 1999; Rajagopalan and Long, 1999). 
HLA-G inhibits Natural Killer (NK) cell-mediated 
cytolysis, cytotoxic CD8+ T-cells, T-cell 
alloproliferation, the maturation of dendritic cells and 
proliferation of T-lymphocytes and NK-cells through 
the interaction with these receptors (reviewed in 
Carosella et al., 2008). 
HLA-G is one of the major key players in fetal-
maternal immune regulation. Expression levels are 
especially high in the first trimester whereas late term 
placentas have decreased levels of HLA-G  
(Yelavarthi et al., 1991). Despite the available amount 
of information, it is still largely unknown how HLA-G 
expression is regulated in relation to its functions and 
complications. Nowadays, it is thought that HLA-G can 
be involved in certain complications during pregnancy 
such as pre-eclampsia (Hviid, 2006). Additionally, it is 
seen that alterations in HLA-G expression can have 
functional consequences. 
This review discusses the role of polymorphisms and 
microRNAs on HLA-G gene expression. Moreover, the 
review focuses on the effect of microRNAs on HLA-G 
gene expression. In addition, the possible role of 
microRNAs in the development of pre-eclampsia will be 
discussed. 
1.1. Polymorphisms and MicroRNAs can Effect 
HLA-G Gene Expression 
1.1.1. Polymorphisms 
Unlike the classical MHCs, HLA-G exhibits low 
polymorphism. HLA-G polymorphisms are present in 
the coding region of HLA-G, the 5’ Upstream 
Regulatory Region (URR) and the 3’ Untranslated 
Region (UTR). It is thought that polymorphisms can 
influence HLA-G gene expression because these may 
affect the expression of certain isoforms and the binding 
of nuclear factors to regulatory regions. Mechanisms 
involved in the generation of polymorphisms are point 
mutations, gene conversions and recombination 
(Cervera et al., 2010). 
1.2. Coding Region 
To date, 49 HLA-G alleles in the coding region are 
acknowledged by the WHO Nomenclature Committee 
for Factors of the HLA System (WHONCFHLAS, 
2012). Of these alleles, there are 15 which display 
HLA-G protein polymorphisms and 2 which are null 
alleles. Most of the Single Nucleotide Polymorphisms 
(SNPs) are found in exon 2, 3 and 4 (Table 1). Some 
polymorphisms are able to change the amino acids. 
For example, in allele HLA-G*01:03 at codon 31 the 
Adenine (A) can be substituted by a Tyrosine (T) 
which creates a serine (ser) instead of a threonine 
(thr). Other substitutions, mostly at the third base of a 
codon, may be nonsynomous where there is no 
change of amino acids.  
However, not all polymorphisms are substitutions. 
The HLA-G*01:05N null allele has a deletion of a 
Cytosine (C) at the last base of codon 129 or the first 
base of codon 130 in exon 3 (Ober et al., 1998;     
Suarez et al., 1997). This causes a frameshift which 
leads to the formation of a stop codon at codon 189. 
Hence, the formation of the α2 region will be altered. 
Consequently, there will be incomplete formation of 
HLA-G1, -G4 and -G5 but not of the isoforms that do 
not contain the α2 region (Discorde et al., 2005;  
Ober et al., 1998). Remarkably, individuals 
homozygous for the HLA-G*01:05N mutation are 
still able to have a term pregnancy without the 
presence of three different isoforms (Casro et al., 
2000; Ober et al., 1998). Indeed, Discorde and co-
workers have confirmed the suggestion that other 
isoforms can compensate for the loss of HLA-G1,-G4 
and-G5 and they have proven to be redundant in 
homozygous individuals (Discorde et al., 2005). 
 The other null allele, HLA-G*01:13N, is defined 
by a C to T substitution in the first base of codon 54 
(Lajoie et al., 2008). This mutation causes a premature 
stop codon in exon 2, the α1 region. As a consequence, 
HLA-G will be truncated and probably even 
nonfunctional. Because of its position in exon 2, the 
mutation will affect all HLA-G isoforms. Therefore it 
is not expected to find homozygous individuals for the 
HLA-G*01:13N allele (Mendes-Junior et al., 2010).  
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Table 1. Overview of polymorphisms in the HLA-G coding region. Data obtained from the (WHONCFHLAS, 2012). Inspiration obtained by (Hviid 2006) and  
(Moscoso et al., 2007). HLA-G alleles are present in the left column and the exons are depicted in the top row. Single nucleotide polymorphisms (SNPs) that 
alter the amino acids have the name of the new amino acid written below. SNPs without an amino acid written below are silent polymorphisms.  
 EXON 2        EXON 3                EXON 4       EXON 5  
 ---------------------------------------------- -------------------------------------------------------------------------------------- -------------------------------------------- ---------------- 
HLA-G alleles 13 27 31 54 57 93 100 104 105 107 110 130 159 169 171 188 189 219 236 258 290 309 
HLA- TCC TAC ACG CAG CCG CAC GGC GGG TCC GGA CTC CTG TAC CAC TAC CAC GTG CGG GCA ACG GGC AGA 
G*01:01:01:01 Ser Tyr Thr Gln Pro His Gly Gly Ser Gly Leu Leu Tyr His Tyr His Val Arg Ala Thr Gly Arg 
#HLA-G*01:01         --A --T       --T                       --G 
HLA-G*01:02     -G-                   --C 
    Arg 
HLA-G*01:03     T--                         --T           --G 
   Ser 
HLA-G*01:04      --A       A- -               --G 
           Ile 
HLA-G*01:05N         --A --T           xTG         TGA       --T --G 
            del     stop 
HLA-G*01:06      --A --T                -T- --T --G 
                    Met 
HLA-G*01:07 -T-       --A           A--                     --G 
 Phe          Ile 
HLA-G*01:08      --A --T              T--      --G 
                  Trp 
HLA-G*01:09         --A --T             C-- 
             His 
HLA-G*01:10    -T- 
   Met 
HLA-G*01:11     -T-   --A           A- - 
   Met        Ile 
HLA-G*01:12   C--   --A 
  His 
HLA-G*01:13N       T-- --A --T 
    Stop 
HLA-G*01:14      --A   -A-             -A-  -T- 
       Asp           Gln  Met 
HLA-G*01:15         --A     -T-     A- - 
        Val   Ile 
HLA-G*01:16      --A --T   -G-             -T- 
         Cys           Met 
HLA-G*01:17         --A --T               -G- C-- 
              Asp His 
# In total, there are 28 variants of the HLA-G*01:01 allele which could not be represent all in this table. Therefore the most common polymorphisms are depicted here 
under HLA-G*01:01. 
 
1.3. Non-Coding Region 
The promoter region of HLA-G (5’URR) contains 
many regulatory elements to provide optimal mRNA 
synthesis. So far, 29 SNPs are identified within the 
5’URR region that may affect binding of nuclear factors 
to the regulatory elements since the SNPs and regulatory 
elements are closely situated to each other (reviewed in 
(Donadi et al., 2011)). 
Polymorphisms are present in the regions -487 to -
475, -754 to -735 and -1201 to -1100 which are 
associated with the heat shock protein element, interferon-
stimulated response element and trophoblast-specific 
response elements respectively (Pyo et al., 2006). Another 
SNP is the -725 Guanine (G)/C/T polymorphism which is 
thought to influence NFκβ binding and transcriptional 
activity (Donadi et al., 2011). More importantly, a linkage 
disequilibrium of the 5’URR with the 3’UTR has been 
described which can influence the RNA stability of HLA-G 
(Donadi et al., 2011; Rousseau et al., 2003).  
In addition to the 5’URR there are also 
polymorphisms associated with the 3’UTR. This region 
has regulatory sequences including the polyA signal and 
microRNA binding sites. The most frequent 
polymorphism of the 3’UTR is the 14bp 
deletion/insertion in exon 8 (Harrison et al., 1993). 
Interestingly, the insertion of 14 base pairs (bp) at the 
3’UTR creates an additional splice event in which the 
first 92bp of exon 8 are spliced out (Hiby et al., 1999). 
Isoforms with this +14bp insertion have decreased 
relative expression levels of HLA-G compared to 
isoforms with a -14bp deletion (Hviid et al., 2003). 
Nonetheless, the removal of these 92bp positively 
influences the stability of the mRNA. Even though 
mRNAs with a +14bp polymorphism express low HLA-
G levels, they have a better resistance to mRNA 
degradation (Rousseau et al., 2003). Therefore, HLA-G 
transcripts will be preserved within the cell and more 
HLA-G can be transcribed. Additionally, the +14bp 
insertion was also found to be associated with a lower 
expression of sHLA-G (Chen et al., 2008). This 
indicates that the 14bp deletion/insertion may greatly 
influence HLA-G gene expression. Furthermore, there 
are two SNPs located at +3142 and +3187 in the 3’UTR 
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which may be involved in the regulation of expression 
levels of HLA-G. The +3142 SNP has a C to G 
substitution which can influence microRNA targeting 
(Tan et al., 2007). This is further discussed in the section 
‘MicroRNAs’. Furthermore, the +3187 polymorphism is 
a G to A mutation which decreases the stability of the 
mRNA and is associated with pre-eclampsia (Yie et al., 
2008). In conclusion, the polymorphisms of the coding 
and non-coding regions discussed here are thought to 
greatly influence the gene expression of HLA-G. It is 
seen that some polymorphisms may affect the expression 
of different HLA-G isoforms or the stability of the 
mRNA. In addition, some polymorphisms are associated 
with complications in pregnancy (Hviid, 2006). However, 
it is still not exactly known what effect these 
polymorphisms have on the function of HLA-G. 
1.4. MicroRNAs  
MicroRNAs are small non-coding RNA molecules of 
about 22 nucleotides which can negatively regulate gene 
expression (Bartel, 2004). Binding of miRNAs to the 
3’UTR of a gene can result in the suppression of 
translation or in the degradation of mRNA. Recently, it 
has been suggested that microRNAs (miRNAs) may 
play a role in the regulation of HLA-G gene expression 
(Veit and Chies, 2009). Additionally, there is a C to G 
polymorphism at position +3142 which has been 
suggested to influence miRNA targeting to the 3’UTR 
region of HLA-G (Tan et al., 2007). Moreover, three 
miRNAs have been found that can bind in the 3’UTR 
end of the HLA-G gene and can inhibit its gene 
expression. These are: miR-148a, miR-148b and miR-
152 (Tan et al., 2007). It has been shown that both miR-
148a and miR-152 can downregulate the expression of 
HLA-G and reduce the binding of the inhibitory receptor 
ILT2 to HLA-G cells (Manaster et al., 2012; Zhu et al., 
2010). As a consequence, NK cell-mediated cytotoxicity 
is increased. Further, it is predicted via in silico analysis 
that more miRNAs can bind to other SNPs in the 
3’UTR, indicating that other miRNAs might be possible 
regulators of HLA-G as well (Castelli et al., 2009). 
These studies provide evidence that miRNAs can be 
important regulators of HLA-G gene expression in 
addition to the earlier described polymorphisms. 
1.5. miR-148a, miR-148b and miR-152 
Expression 
MicroRNAs bind to a seed region, which is 
suggested to be important in target recognition. This 
region consist of 2-7 nucleotides that are perfectly 
complementary to that of the mRNA. The seed region of 
miR-148a and miR-148b is the same and the predicted 
binding energies are similar (Manaster et al., 2012;    
Tan et al., 2007). Therefore it is thought that these two 
miRNAs have similar activity. Furthermore, in all three 
miRNA (miR-148a, miR-148b and miR-152) seed 
regions, the +3142 C to G SNP is located. This SNP was 
suggested to influence HLA-G expression since the 
binding energies of the C variant were lower than the G 
variant (Tan et al., 2007). Though binding of miRNAs 
to the G variant is more stable and expresses lower 
HLA-G expression. Additionally, the +3142G 
genotype of the mother showed to be protective 
against the development of asthma in their children 
(Tan et al., 2007). Contrarily, Manaster and co-
workers showed that the +3142 polymorphism does 
not influence the in vitro miRNA targeting of HLA-G 
(Manaster et al., 2012). Both alleles (+3142C or G) 
are evenly distributed throughout the population 
(TIHC, 2003). Thus in order to investigate if the 
+3142C to G polymorphism influences the expression 
of HLA-G and thereby also the clinical outcome of a 
pregnancy, the genotype of normal and complicated 
pregnancies have to be determined. 
All three suggested miRNAs are able to bind to their 
target site within the 3’UTR of HLA-G (Manaster et al., 
2012; Tan et al., 2007; Zhu et al., 2010). In order to bind 
to HLA-G, microRNAs must be expressed in EVT cells. 
Zhu and co-workers showed that low levels of miR-152 are 
expressed in the HLA-G high JEG3 cell line (Zhu et al., 
2010). Since JEG3 is a human placenta choriocarcinoma 
cell line that is used to study EVT cells in vitro it can be 
assumed that results will resemble in vivo situations. In 
addition, the expression levels of miR-148a and miR-
148b were tested in both primary Cytotrophoblast Cells 
(CTB) and JEG3 cells (Manaster et al., 2012; Tan et al., 
2007). Both cell types showed low expression levels of 
miR-148a and miR-148b. Although the in vitro 
expression of these miRNAs is low, it is likely that they 
can still be produced in EVT cells. Moreover, it is 
expected to find low microRNA expression in 
uncomplicated pregnancies. In fact, the expression of 
microRNAs should be low during pregnancy because they 
are likely to negatively regulate HLA-G expression and 
thus lead to complications. Furthermore, Dicer, a protein 
involved in the miRNA processing machinery, was found 
to be present in villous and extravillous trophoblast cells, 
whereas it was absent in syncytiotrophoblast cells (Forbes 
et al., 2012). All together this is an indication that miR-
148a, miR-148b and miR-152 can be expressed and 
produced in EVT cells. 
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The origin of miR-148a, miR-148b and miR-152 can 
be either canonical or intronic. In the canonical pathway 
the miRNA is transcribed from its own promoter and 
forms a hairpin structure after which it is processed in 
the nucleus and cytoplasm (Miyoshi et al., 2010). A 
minority of microRNAs are intronic (mirtrons). Mirtrons 
are found in the introns of pre-mRNAs and are not 
transcribed from their own promoter but instead 
expressed from their host transcript (Bartel, 2004). No 
co-expression of miR-148a is expected to be found since 
there is no specific gene located near this miRNA. On 
the contrary, miR-148b and miR-152 are located within 
the coatomer protein complex subunit zeta 1 (COPZ1) 
and COPZ2 respectively. miR-152 is located within an 
intron of COPZ2 and therefore it can be thought that this 
miRNA can be simultaneously expressed with the 
COPZ2 transcript. Indeed, it was found that the 
expression of these two transcripts are similar in human 
endometrial cancer cell lines (Tsuruta et al., 2011). 
Therefore it can be suggested that miR-152 is 
regulated via the intronic pathway. In contrast, miR-
148b had no coherent expression with its host gene 
COPZ1 (Liang et al., 2007). This indicates that miR-
148b, just like miR-148a, is most likely regulated via the 
canonical pathway. 
Several articles already showed that the in vitro 
binding of miR-148a, miR-148b and miR-152 to the 
3’UTR of HLA-G resulted in a decreased expression of 
HLA-G protein. However, the mechanism of this 
inhibition is still an issue of discussion. Manaster and 
coworkers show that mRNA degradation is involved, 
whereas Zhu and coworkers show inhibition of 
translation is the responsible mechanism. It is possible 
that miRNA mediated repression of HLA-G expression 
functions via both mechanisms. The miRNA will act via 
mRNA cleavage or inhibition of translation depending 
on the amount of complementary sequence of the 
mRNA (Bartel, 2004). 
Conclusively, it is plausible that miR-148a, miR-
148b and miR-152 influence HLA-G expression. The 
microRNAs are likely to be expressed and processed in 
EVT cells. Genotypes of normal and complicated 
pregnancies have to be determined to examine if the 
+3142C to G polymorphism can additionally influence 
HLA-G expression. More research is needed to 
investigate which mechanism is involved in HLA-G 
repression. In addition, it is important to examine when 
during pregnancy these miRNAs are expressed to identify 
the impact that miRNAs can have on gene expression and 
consequently on pregnancy. 
1.6. Functional Consequences of HLA-G 
Targeting by microRNAs 
Binding of miR-148a, miR-148b and miR-152 to 
HLA-G resulted in a decreased (s)HLA-G expression. 
Since the 3’UTR is present in all HLA-G isoforms, it is 
likely that miRNAs can regulate the expression of all 
HLA-G isoforms. This altered HLA-G expression can 
have functional complications. As described earlier, 
repression of HLA-G by miRNAs diminished the 
interaction with ILT2 and enhanced NK cell-mediated 
killing (Manaster et al., 2012). Another important 
function of HLA-G in protecting the fetus besides 
inhibition of NK-cell mediated cell death/apoptosis, is 
the inhibition of Cytotoxic Lymphocyte (CTL) 
responses. HLA-G is able to suppress the allocytotoxic 
T lymphocyte responses against paternal antigens of the 
fetus in vitro (Kapasi et al., 2000). This induces an 
protective Th2 response in pregnancy, in which IL-10 is 
upregulated and the expression levels of TNF-α and IFN-
γ are reduced. However, it was found that lower levels of 
HLA-G were unable to suppress CTLs to the same extent 
as normal HLA-G levels and thereby it promotes the Th1 
response. This can have serious consequences for 
pregnancy. Therefore it is essential to examine if 
microRNAs can be involved in the inhibition of CTL 
suppression via the reduced expression of HLA-G. 
Furthermore, it would be interesting to investigate if other 
functions of HLA-G are impaired as well because of the 
induction of microRNAs. 
An in silico screening of miRNAs that are potentially 
involved in the regulation of HLA-G revealed that miR-
19a had the exact same binding energy as miR-148a, 
miR-148b and miR-152 and also has a target site which 
included the +3142 polymorphism (Castelli et al., 2009). 
This indicates that miR-19a can have an important 
function in the regulation of HLA-G as well. Recently, 
miR-19a expression was found to be upregulated by 
shear stress in human umbilical cord endothelial cells 
(Qin et al., 2010). The expression of this miRNA 
inhibited the cell cycle of endothelial cells. It would be 
interesting to test if miR-19a can also have a potential 
role in the regulation of HLA-G in EVT cells. This can 
be done by verifying miR-19a binding to HLA-G and 
measuring the activity of HLA-G in the presence of 
miR-19a. Additionally, it is interesting to investigate if 
miR-19a could be associated to cell cycle processes in 
EVT cells as well. It might be that miR-19a is involved 
in vascular remodeling.  
Ayla Carmel Kempers et al. / American Journal of Immunology, 2012, 8 (4), 136-145 
 
141 
 
Science Publications
 
AJI 
Several functions of HLA-G can be diminished upon 
low expression of HLA-G. However, the cause of the 
reduced HLA-G expression is still unknown and it is 
possible that microRNAs are involved. The NK cell-
mediated cell death has shown to be enhanced 
through inhibition of HLA-G by miRNAs. Here, we 
suggest that CTL mediated cell death could also be 
regulated via the same mechanism. Additionally, 
miR-19a would be a good candidate for further 
investigation of its involvement in HLA-G expression 
and of its functions. 
1.7. The Involvement of microRNAs in Pre-
Eclampsia 
Reduced expression of HLA-G by the negative 
regulation of miRNAs may influence the amount of 
sHLA-G and membrane-bound HLA-G during 
pregnancy. It is possible that miRNAs indirectly can 
cause complications in pregnancy, such as pre-
eclampsia. Naturally, this will depend on several factors 
such as the gestational age of the fetus, which miRNAs 
are expressed and when during pregnancy these 
miRNAs are expressed. 
Pre-eclampsia is a pathological condition that can 
occur from 20 weeks of gestation onwards in which 
maternal blood pressure rises and oedema and 
proteinuria develop (Duley, 2009). This condition 
occurs in 5-8% of all pregnancies and can lead to 
eclampsia. Both pre-eclampsia and eclampsia are 
nowadays still a major cause of maternal and 
perinatal mortality and morbidity. Currently, there are 
a few interventions to prevent pre-eclampsia but there 
is no treatment except for the termination of 
pregnancy or delivery (WHO, 2012). 
During pregnancy invasive EVT cells are able to 
remodel the uterine arteries in order to have a high flow and 
low resistance blood supply to the fetus (Huppertz et al., 
2012). It has been found that in pre-eclampsia EVT cells 
start to differentiate but cannot complete differentiation. 
Therefore EVTs are less able to invade the uterine 
arteries and as a consequence, the arteries will have a 
low flow and high resistance (Lim et al., 1997). This 
inadequate blood supply to the fetus can eventually 
result in poor growth or prematurity. Although the 
exact cause of pre-eclampsia is not determined yet, 
there are indications that many factors are involved. 
One of these factors is the genetic background of 
HLA-G expression. 
In a pre-eclamptic pregnancy, the expression of 
HLA-G is much lower compared to control pregnancies 
at both mRNA and protein level   (Hara et al., 1996; 
Lim et al., 1997; O’Brien et al., 2001; Yie et al., 2004; 
Zhu et al., 2012). The exact cause of this reduction in 
HLA-G level has yet to be determined. Considering that 
miRNAs negatively regulate HLA-G expression, it can 
be hypothesized that miRNAs are involved in the 
development of pre-eclampsia. To test this hypothesis, 
sHLA-G and miR-148a, miR-148b and miR-152 levels 
need to be tested from the blood of normal and 
pre-eclamptic pregancies. 
There are already some indications that certain 
microRNAs are involved. Several studies aimed to 
identify miRNAs involved in pre-eclampsia by 
comparing miRNA expression between normal and 
pre-eclamptic placentas (Mayor-Lynn et al., 2011; 
Pineles et al., 2007; Zhu et al., 2009). Each study found 
various miRNAs that were either up- or downregulated 
in pre-eclamptic placentas. Zhu and coworkers were 
able to identify almost a two-fold increase of miR-152 
expression in pre-eclamptic placentas (Zhu et al., 2009). 
This is in line with the suggestion that miR-152 could be 
involved in the development of pre-eclampsia by the 
downregulation of HLA-G. However, they also found a 
decreased expression of miR-19a. Although this 
conflicts with our hypothesis that we discussed earlier, it 
does acknowledge the suggestion that miR-19a can be 
involved in vascular remodeling. Additionally, other 
microRNAs with other targets than HLA-G are found 
to be involved in the modulation of angiogenesis in 
Human Umbilical Vein Endothelial Cells (HUVEC) 
(Poliseno et al., 2006). This implies that more miRNAs 
might play a role in the vascular organization in pre-
eclampsia. 
One specific microRNA found in all three studies is 
miR-210 (Mayor-Lynn et al., 2011; Pineles et al., 2007; 
Zhu et al., 2009). In two studies, miR-210 was found to 
be increased by a three-fold in (severe) pre-eclampsia, 
while Lynn and coworkers found a small 
downregulation. In another study of miR-210 it was 
found that this microRNA is overexpressed in hypoxic 
conditions and causes a reduction in the formation of 
capillary-like structures (Fasanaro et al., 2008). 
Furthermore, it decreases endothelial cell migration 
and survival. Since hypoxia is an important hallmark 
of pre-eclampsia, this can indicate that miR-210 is 
involved in the development of pre-eclampsia.  
Pre-eclampsia is caused by the underdevelopment of 
the uterine arteries and it can be thought that both a 
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change in NK cell-mediated killing and the enhanced 
CTL responses can be responsible for this complication. 
Kaposi and coworkers already suggested that CTL 
responses may influence the development of pre-
eclampsia. In pre-eclamptic pregnancies there is a Th1 
response whereas normal pregnancies are characterized 
by a Th2 response. The Th1 response, which results 
from the enhanced allocytotoxic responses, is an 
indication that this function of HLA-G might be 
involved in the development of pre-eclampsia. 
With regard to the suggestion that miRNAs are 
involved in the development of pre-eclampsia and the in 
vitro results that show an increase in NK cell-mediated 
cell death in the presence of miRNAs, it can be 
hypothesized that there will be a difference in NK cell-
mediated cell death between normal and pre-eclamptic 
placentas. At the moment, there is no consensus yet 
about the NK levels in normal versus pre-eclamptic 
placentas. Borzychowski and coworkers found a 
significant increase in the NK1/NK2 ratios in pre-
eclamptic pregnancy versus normal pregnancy 
(Borzychowski et al., 2005). On the other hand, 
Sánchez-Rodríguez and coworkers found no differences 
in NK cells from pre-eclamptic and normal pregnancies 
(Sanchez-Rodriguez et al., 2011). More research has to 
be done to identify the proportion and activity of NK 
cells in pre-eclampsia. In order to investigate if miRNAs 
are involved, the activity and amount of NK cells in pre-
eclamptic and normal placentas should be tested 
together with the levels of miRNA expression in the 
same samples. 
To summarize, microRNAs can be potentially 
involved in the aberrant gene expression of HLA-G in 
pre-eclampsia. We hypothesize that miR-148a, miR-
148b and miR-152 can be associated with pre-eclampsia 
via the downregulation of HLA-G. We also suggest that 
both NK cell-mediated cell death and the activation of 
CTL responses, by the reduced expression of HLA-G 
via miRNA binding, can cause the development of 
pre-eclampsia.  
2. CONCLUSION 
The HLA-G gene expression of fetal EVT cells can 
be affected by both polymorphisms and microRNAs. 
Until recently, there was not much focus on the 
involvement of microRNAs in pregnancy. However, last 
years it becomes apparent that the placenta is an 
important site for miRNA expression and that they 
might be important regulators in placental development. 
Recently, miR-148a, miR-148b and miR-152 have 
found to bind the 3’UTR of HLA-G and reduce the 
expression of HLA-G. Reduced expression levels of 
HLA-G have shown to have functional effects. Further 
research should focus on the consequences of this 
microRNA dependent HLA-G suppression. It was 
already shown that NK cell-mediated killing is 
enhanced. Nevertheless, it can be thought that other 
functions of HLA-G, for example CTL mediated cell 
death, are altered. In addition, more microRNAs, such as 
miR-19a, can be tested for their involvement in HLA-G 
expression and vascular remodeling.  
Reduced expression levels of HLA-G were observed 
in pregnancies with pre-eclampsia and (recurrent) 
spontaneous abortions. This indicates that HLA-G is an 
important factor in the development of pregnancy 
disorders. Pre-eclampsia is characterized by the 
reduction of HLA-G and the induction of a Th1 
response. Here, we hypothesize that miRNAs may be 
one of many factors in involved in the development of 
pre-eclampsia since miRNAs have proven to reduce the 
HLA-G expression. Examination of the role of miR-
148a, miR-148b and miR-152 and other miRNAs in 
HLA-G expression and in pathological conditions of 
pregnancy are needed to confirm this suggestion. This 
information will eventually create a better 
understanding of the tightly regulated mechanisms 
during pregnancy. 
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